Clinical Trial Update: Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated gene-modified autologous white blood cells followed by interleukin-2 and a cancer vaccine in metastatic melanoma; the study status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cancer vaccine therapy
• Gene-modified autologous leukocytes (gene-modified white blood cells)
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Melanoma (Skin) | Phase 1 | Status: COMPLETED